Osteoprotegerin
Osteoprotegerin (OPG) belongs to the tumor necrosis factor receptor (TNFR) superfamily. Osteoprotegerin blocks the RANKL-RANK interaction as well as the binding of TRAIL to its receptor. Osteoprotegerin activates NF-κB to induce the expression of ICAM-1, VCAM-1 and E-selectin, and activates the phosphorylation of ERK1/2. Osteoprotegerin regulates osteoclast activity, inhibits osteoclast maturation and formation, bone lysis and bone resorption, and increases bone mass. Osteoprotegerin regulates vascular endothelial cell function. Osteoprotegerin can be used in the research of cardio-cerebrovascular and bone-related diseases.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 19220-35-0
- Formel: C18H32O2
- Molecular Weight:280.45
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
Osteoprotegerin dose-dependently upregulates the expression of AT1 receptors in human vascular smooth muscle cells and cells derived from atherosclerotic plaques, and directly activates the phosphorylation of ERK1/2 in vitro[1].
Osteoprotegerin inhibits RANKL-induced matrix metalloproteinase activity in human vascular smooth muscle cells *in vitro* by sequestering RANKL and preventing its binding to RANK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 19220-35-0
-
Molecular Weight 280.45
-
Formel C18H32O2
-
SMILES
O=C(CCCCCC#CCCCCCCCCCC)O
-
Synonyms
OPG
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Dutka M, et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. Heart failure reviews. 2022 Jul;27(4):1395-1411. [Content Brief]
[2]. Payr S, et al. Direct comparison of 3D and 2D cultivation reveals higher osteogenic capacity of elderly osteoblasts in 3D. Journal of orthopaedic surgery and research. 2021 Jan 06;16(1):13. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Osteoprotegerin Related Classifications
HY-183516 Related Classifications
Powered by Bioz